Many of the most devastating infectious diseases are caused by RNA viruses, and Model Medicines is working on one compound to ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

But the report, on the experiences of 13 patients, found that the drug had no benefit for some people and that some who ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But ... that traditional medical records may overlook. Extended antiviral courses have precedent in other conditions like HIV and hepatitis C ...

Pfizer’s decision to offload $3.05 billion worth of shares in Haleon is a strategic move driven by shifting priorities in a ...

Historically, COVID-19 symptoms have been fevers or chills, cough, shortness of breath, cough, congestion or a runny nose, ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) were down 0.2% during trading on Friday . The company traded as low as $26.52 and last traded at $26.57. Approximately 5,717,203 shares changed hands ...

While Pfizer shares soared 2021 on the strength of the company’s Covid-19 products, the stock has collapsed alongside demand. Sales of the Covid-19 antiviral Paxlovid were $2.7 billion for the ...